[go: up one dir, main page]

DE69738944D1 - Retrovirale vektoren - Google Patents

Retrovirale vektoren

Info

Publication number
DE69738944D1
DE69738944D1 DE69738944T DE69738944T DE69738944D1 DE 69738944 D1 DE69738944 D1 DE 69738944D1 DE 69738944 T DE69738944 T DE 69738944T DE 69738944 T DE69738944 T DE 69738944T DE 69738944 D1 DE69738944 D1 DE 69738944D1
Authority
DE
Germany
Prior art keywords
dependent
hiv
rev
transcription unit
provirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738944T
Other languages
English (en)
Inventor
Susan Mary Kingsman
Alan John Kingsman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Application granted granted Critical
Publication of DE69738944D1 publication Critical patent/DE69738944D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/48Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
DE69738944T 1996-10-17 1997-10-17 Retrovirale vektoren Expired - Lifetime DE69738944D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9621679.1A GB9621679D0 (en) 1996-10-17 1996-10-17 Improved retroviral vectors
PCT/GB1997/002859 WO1998017817A1 (en) 1996-10-17 1997-10-17 Retroviral vectors

Publications (1)

Publication Number Publication Date
DE69738944D1 true DE69738944D1 (de) 2008-10-09

Family

ID=10801597

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738944T Expired - Lifetime DE69738944D1 (de) 1996-10-17 1997-10-17 Retrovirale vektoren

Country Status (8)

Country Link
US (2) US20020141978A1 (de)
EP (1) EP0931157B1 (de)
JP (1) JP2001502904A (de)
AT (1) ATE406452T1 (de)
AU (1) AU4712497A (de)
DE (1) DE69738944D1 (de)
GB (2) GB9621679D0 (de)
WO (1) WO1998017817A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2291025T3 (es) 1998-05-13 2008-02-16 Genetix Pharmaceuticals Inc. Celulas lentivirales de empaquetamiento.
EP1088086A4 (de) 1998-06-24 2003-01-08 Musc Found For Res Dev Gewebe-spezifische sowie ziel-rna-spezifische ribozyme
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
CA2365901A1 (en) 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1240333B1 (de) 1999-11-16 2008-04-09 Geneart Ag Das genom des hiv-1 intersubtyps (c/b') und seine anwendungen
EP1702983A3 (de) 2000-04-13 2007-01-10 Medical University of South Carolina Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
WO2012065105A2 (en) * 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306631A (en) * 1987-08-21 1994-04-26 University Of Colorado Foundation, Inc. Compositions and method for inhibition of HIV production
US6544771B1 (en) * 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
EP0588914A1 (de) * 1991-05-29 1994-03-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Eukaryotische expressionsvektoren mit steuerung der rns-prozessierung
WO1995030755A1 (fr) * 1994-05-10 1995-11-16 Hisamitsu Pharmaceutical Co., Inc. Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production

Also Published As

Publication number Publication date
GB9904143D0 (en) 1999-04-14
US20020141978A1 (en) 2002-10-03
GB9621679D0 (en) 1996-12-11
ATE406452T1 (de) 2008-09-15
JP2001502904A (ja) 2001-03-06
EP0931157A1 (de) 1999-07-28
US20060024279A1 (en) 2006-02-02
EP0931157B1 (de) 2008-08-27
GB2331989B (en) 2000-09-27
GB2331989A (en) 1999-06-09
WO1998017817A1 (en) 1998-04-30
AU4712497A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
Lavrentieva et al. High polymorphism level of genomic sequences flanking insertion sites of human endogenous retroviral long terminal repeats
DE69534733D1 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
Ling et al. The solitary long terminal repeats of ERV-9 endogenous retrovirus are conserved during primate evolution and possess enhancer activities in embryonic and hematopoietic cells
WO2001071042A8 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
NO20001497L (no) Ekspresjon av endogene gener ved ikke-homolog rekombinasjon av en vektorkonstrukt med cellulært DNA
EP0385558A3 (de) Materialien und Verfahren für "genome walking"
DE69534421D1 (de) Cytoplasmatische Inhibition des Genexpression
Klasens et al. Inhibition of polyadenylation by stable RNA secondary structure
ATE510920T1 (de) Dna-sequenzen zur regulation der transkription
DE69738944D1 (de) Retrovirale vektoren
ATE91715T1 (de) Genexpressionssystem.
DE69730139D1 (de) Neuartige expressionsvektoren
DE69323199D1 (de) Gen für die ataxia-telangiectasia komplementationsgruppe d
Tajima et al. Mutant tax protein from bovine leukemia virus with enhanced ability to activate the expression of c-fos
DE68912228D1 (de) Verfahren für die Rettung von DNS und für den Nachweis von Mutationen in Markiergenen.
SE8604636D0 (sv) Sett att uttrycka gener med hjelp av bacillus brevis
ATE72837T1 (de) Vielfach amplifizierbare vektoren fuer hohe expression exogener dns.
Mischiati et al. Characterization of a major histocompatibility complex class II X-box-binding protein enhancing tat-induced transcription directed by the human immunodeficiency virus type 1 long terminal repeat
HUP0004857A2 (hu) T. variabilisból származó D-aminosav oxidáz promótere
ATE259421T1 (de) Dna-virus-vektoren und verfahren zu ihrer herstellung
WO2002029101A3 (en) Methods for cloning, sequencing and expressing genes from complex microbial populations
CA2289907A1 (en) Eukaryotic and retroviral antisense initiator elements
Lembo et al. Trans-activation of the mouse cytomegalovirus immediate early gene enhancer by ras oncogenes
Peberdy Genetic engineering in relation to enzymes.
DK561889D0 (da) Ekspressionsforstaerker samt anvendelse heraf til forhoejelse af udbyttet ved ekspression af rekombinante gener

Legal Events

Date Code Title Description
8364 No opposition during term of opposition